Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Classical hematology 1CNS 1Breast 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

Carboplatin 334Pemetrexed 275Cisplatin 227Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 41130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × prexasertib × Thoracic × Clear all
NCT02735980 2020-03-17

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

Eli Lilly and Company

Phase 2 Completed
133 enrolled 20 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡